Peter Ding, Allorion Therapeutics co-founder and CEO

A fledg­ling transpa­cif­ic biotech grabs a launch round to dive in­to on­col­o­gy and au­toim­mune re­search

Pre­ci­sion-med biotech Al­lo­ri­on Ther­a­peu­tics is ex­pand­ing — and now has tens of mil­lions of dol­lars more to work with.

The Nat­ick, MA-based com­pa­ny an­nounced in a state­ment this morn­ing that it closed a Se­ries A round, bring­ing in $40 mil­lion. Shang­hai VC Qim­ing Ven­ture Part­ners led the round, which al­so in­cludes a num­ber of both new and old in­vestors — Oc­ta­gon Cap­i­tal, IDG Cap­i­tal and TF Cap­i­tal, to name a few.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.